Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | TPSAB1 | Q15661 | 9/20 | 0.57 |
| ▸ | F2 | P00734 | 8/20 | 0.57 |
| ▸ | TPSD1 | Q9BZJ3 | 6/20 | 0.57 |
| ▸ | TPSG1 | Q9NRR2 | 6/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 5/20 | 0.57 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.57 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.57 |
| ▸ | PLG | P00747 | 2/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12466797 | 0.89 | MEN1 (0.77) | MEN1KMT2ATPSAB1F2TPSD1 | |
| SCHEMBL12685793 | 0.86 | MEN1 (0.65) | MEN1KMT2ATPSAB1TPSD1TPSG1 | |
| SCHEMBL12466643 | 0.86 | MEN1 (0.65) | MEN1KMT2ATPSAB1TPSD1TPSG1 | |
| SCHEMBL12466583 | 0.77 | MEN1 (0.85) | MEN1KMT2AGRIN2B | |
| SCHEMBL12466909 | 0.76 | KMT2A (0.74) | MEN1KMT2ATPSAB1GRIN2B | |
| SCHEMBL12685846 | 0.75 | MEN1 (0.85) | MEN1KMT2ATPSAB1TPSD1TPSG1 | |
| SCHEMBL12685780 | 0.75 | MEN1 (0.85) | MEN1KMT2ATPSAB1GRIN2B | |
| Hydrochloric Acid SCHEMBL12466326 | 0.74 | MEN1 (0.83) | MEN1KMT2ATPSAB1TPSD1TPSG1 | |
| SCHEMBL12466321 | 0.74 | MEN1 (0.67) | MEN1KMT2ATPSAB1TPSD1TPSG1 | |
| SCHEMBL12466499 | 0.74 | KMT2A (0.67) | MEN1KMT2ATPSAB1TPSD1TPSG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130324556-A1 | Protease Activated Receptor 2 (PAR2) Antagonists | PROXIMAGEN LTD. (GB) | 2013-12-05 | — | — | US | claimed |
| EP-2668157-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | Proximagen Limited (GB) | 2013-12-04 | — | — | EP | claimed |
| WO-2012101453-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | PROXIMAGEN LTD. (GB) | 2012-08-02 | — | — | WO | claimed |
| US-20130324556-A1 | Protease Activated Receptor 2 (PAR2) Antagonists | PROXIMAGEN LTD. (GB) | 2013-12-05 | — | — | US | disclosed |
| EP-2668157-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | Proximagen Limited (GB) | 2013-12-04 | — | — | EP | disclosed |
| WO-2012101453-A1 | PROTEASE ACTIVATED RECEPTOR 2 (PAR2) ANTAGONISTS | PROXIMAGEN LTD. (GB) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324556-A1 | Protease Activated Receptor 2 (PAR2) Antagonists | F2RL1, F2R, F2RL3 | MEN1 1376/4885KMT2A 2337/4885TPSAB1 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.